CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
Curis, Inc.
Mayo Clinic
Pfizer
Memorial Sloan Kettering Cancer Center
Incyte Corporation
Amgen
National Institutes of Health Clinical Center (CC)
Dren Bio
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
Roswell Park Cancer Institute
National Cancer Institute (NCI)
Instituto de Investigación Biomédica de Salamanca
AstraZeneca
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
University of Texas Southwestern Medical Center
Novartis
BeOne Medicines
Wake Forest University Health Sciences
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
Kelonia Therapeutics, Inc.
University of Washington
M.D. Anderson Cancer Center
City of Hope Medical Center
National Cancer Institute (NCI)
AVM Biotechnology Inc
New York Medical College
New York Medical College
BeOne Medicines
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Lyell Immunopharma, Inc.
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
BeOne Medicines
AstraZeneca
Columbia University
Children's Hospital of Philadelphia
Children's Hospital of Philadelphia
BeOne Medicines
BeOne Medicines
Nantes University Hospital
Ohio State University Comprehensive Cancer Center
BeOne Medicines
Ohio State University Comprehensive Cancer Center
Aarhus University Hospital
Beijing Tongren Hospital